Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 260 participants.
Also called NCT05487261
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 260 participants
- Registry
-
NCT05487261
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland
- Registry status
- Unknown status
Technical summary
Registry record NCT05487261. Randomized; double masking; primary purpose treatment. Start 2022-12-13 (actual); primary completion 2025-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction
- Acronym
- PRESENT-HF
- Condition
- Heart Failure
- Intervention (Drug)
- Sacubitril-valsartan
- Intervention (Drug)
- Enalapril
- Intervention (Drug)
- placebo
- Intervention (Drug)
- Placebo
- Lead sponsor
- Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań
- Collaborator
- Medical Research Agency, Poland
- Collaborator
- Medical University of Bialystok
- Collaborator
- University of Opole
- Collaborator
- Medical University of Gdansk
- Collaborator
- Medical University of Silesia
Record details
- Record id
cardio:ct-nct05487261- Content hash
aeec2ab6cd75b2d17920836352776a9d163db9a0e50167927a8065af92eb5e37